ZB002

Phase 1Small molecule

ZZenas BioPharma (USA), LLC

ZB002 is one of 31 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rheumatoid ArthritisActive, not recruiting

Rheumatoid ArthritisPhase 1

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Orencia

Bristol-Myers Squibb

Preclinical

47 2

Actemra

Cimzia

30 4

Remicade

OOrganon and Co

Preclinical

43 5

Enbrel

IImmunex

Preclinical

64 6

Actos

Takeda

Preclinical

2 7

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 8

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 9

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 10

Cimzia

UCB

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis

Recruiting·ZZenas BioPharma (USA), LLC·Phase 1·NCT05638854·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ZB002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ZB002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ZB002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Zenas BioPharma (USA), LLC company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: ZZenas BioPharma (USA), LLC

ZB002

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

References

Drug Info

Quick Facts

Related News